Cargando…

Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?

BACKGROUND: Lymph node invasion is associated with poor outcome in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with RCC within a single center from 2001 to 2018 were retrospectively obtained from the Chang Gung Research Database. Patient gender, physical status, Charlson...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Kai-Jie, Chen, Sy-Yuan, Lin, Po-Hung, Liu, Chung-Yi, Joon, Aron Y., Yang, Yu-Kuan, Shao, I.-Hung, Kan, Hung-Chen, Chu, Yuan-Cheng, Huang, Liang-Kang, Chang, Ying-Hsu, Chuang, Cheng-Keng, Weng, Wen-Hui, Pang, See-Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319662/
https://www.ncbi.nlm.nih.gov/pubmed/37291441
http://dx.doi.org/10.1245/s10434-022-12979-y
_version_ 1785068286311923712
author Yu, Kai-Jie
Chen, Sy-Yuan
Lin, Po-Hung
Liu, Chung-Yi
Joon, Aron Y.
Yang, Yu-Kuan
Shao, I.-Hung
Kan, Hung-Chen
Chu, Yuan-Cheng
Huang, Liang-Kang
Chang, Ying-Hsu
Chuang, Cheng-Keng
Weng, Wen-Hui
Pang, See-Tong
author_facet Yu, Kai-Jie
Chen, Sy-Yuan
Lin, Po-Hung
Liu, Chung-Yi
Joon, Aron Y.
Yang, Yu-Kuan
Shao, I.-Hung
Kan, Hung-Chen
Chu, Yuan-Cheng
Huang, Liang-Kang
Chang, Ying-Hsu
Chuang, Cheng-Keng
Weng, Wen-Hui
Pang, See-Tong
author_sort Yu, Kai-Jie
collection PubMed
description BACKGROUND: Lymph node invasion is associated with poor outcome in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with RCC within a single center from 2001 to 2018 were retrospectively obtained from the Chang Gung Research Database. Patient gender, physical status, Charlson Comorbidity Index, tumor side, histology, age at diagnosis, and body mass index (BMI) were compared. The overall survival (OS) and cancer-specific survival (CSS) of each group were estimated using the Kaplan–Meier method. Log-rank tests were used to compare between the subgroups. RESULTS AND CONCLUSIONS: A total of 335 patients were enrolled, of whom 76 had pT(3)N(0)M(0), 29 had pT(1–3)N(1)M(0), 104 had T(1–4)N(0)M(1), and 126 had T(1–4)N(1)M(1) disease. Significant OS difference was noted between pT(3)N(0)M(0) and pT(1–3)N(1)M(0) groups with 12.08 years [95% confidence interval (CI), 8.33–15.84] versus 2.58 years (95% CI, 1.32–3.85), respectively (P < 0.005). No significant difference was observed in OS between pT(1–3)N(1)M(0) and T(1–4)N(0)M(1) groups with 2.58 years (95% CI, 1.32–3.85) versus 2.50 years (95% CI, 1.85–3.15, P = 0.72). The OS of N(1)M(1) group was worse than that of N(0)M(1) group with 1.00 year (95% CI, 0.74–1.26) versus 2.50 years (95% CI, 1.85–3.15, P < 0.05). Similar results were also observed in CSS. In summary, we claim that RCC with lymph node (LN) invasion should be reclassified as stage IV disease in terms of survival outcome.
format Online
Article
Text
id pubmed-10319662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-103196622023-07-06 Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease? Yu, Kai-Jie Chen, Sy-Yuan Lin, Po-Hung Liu, Chung-Yi Joon, Aron Y. Yang, Yu-Kuan Shao, I.-Hung Kan, Hung-Chen Chu, Yuan-Cheng Huang, Liang-Kang Chang, Ying-Hsu Chuang, Cheng-Keng Weng, Wen-Hui Pang, See-Tong Ann Surg Oncol Urologic Oncology BACKGROUND: Lymph node invasion is associated with poor outcome in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with RCC within a single center from 2001 to 2018 were retrospectively obtained from the Chang Gung Research Database. Patient gender, physical status, Charlson Comorbidity Index, tumor side, histology, age at diagnosis, and body mass index (BMI) were compared. The overall survival (OS) and cancer-specific survival (CSS) of each group were estimated using the Kaplan–Meier method. Log-rank tests were used to compare between the subgroups. RESULTS AND CONCLUSIONS: A total of 335 patients were enrolled, of whom 76 had pT(3)N(0)M(0), 29 had pT(1–3)N(1)M(0), 104 had T(1–4)N(0)M(1), and 126 had T(1–4)N(1)M(1) disease. Significant OS difference was noted between pT(3)N(0)M(0) and pT(1–3)N(1)M(0) groups with 12.08 years [95% confidence interval (CI), 8.33–15.84] versus 2.58 years (95% CI, 1.32–3.85), respectively (P < 0.005). No significant difference was observed in OS between pT(1–3)N(1)M(0) and T(1–4)N(0)M(1) groups with 2.58 years (95% CI, 1.32–3.85) versus 2.50 years (95% CI, 1.85–3.15, P = 0.72). The OS of N(1)M(1) group was worse than that of N(0)M(1) group with 1.00 year (95% CI, 0.74–1.26) versus 2.50 years (95% CI, 1.85–3.15, P < 0.05). Similar results were also observed in CSS. In summary, we claim that RCC with lymph node (LN) invasion should be reclassified as stage IV disease in terms of survival outcome. Springer International Publishing 2023-06-08 2023 /pmc/articles/PMC10319662/ /pubmed/37291441 http://dx.doi.org/10.1245/s10434-022-12979-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Urologic Oncology
Yu, Kai-Jie
Chen, Sy-Yuan
Lin, Po-Hung
Liu, Chung-Yi
Joon, Aron Y.
Yang, Yu-Kuan
Shao, I.-Hung
Kan, Hung-Chen
Chu, Yuan-Cheng
Huang, Liang-Kang
Chang, Ying-Hsu
Chuang, Cheng-Keng
Weng, Wen-Hui
Pang, See-Tong
Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
title Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
title_full Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
title_fullStr Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
title_full_unstemmed Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
title_short Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
title_sort should patients with renal cell carcinoma and pathological nodal invasion be classified as having stage iv disease?
topic Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319662/
https://www.ncbi.nlm.nih.gov/pubmed/37291441
http://dx.doi.org/10.1245/s10434-022-12979-y
work_keys_str_mv AT yukaijie shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT chensyyuan shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT linpohung shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT liuchungyi shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT joonarony shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT yangyukuan shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT shaoihung shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT kanhungchen shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT chuyuancheng shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT huangliangkang shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT changyinghsu shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT chuangchengkeng shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT wengwenhui shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease
AT pangseetong shouldpatientswithrenalcellcarcinomaandpathologicalnodalinvasionbeclassifiedashavingstageivdisease